8 Jan 2021
Afferent Medical Solutions announces a £1.1 million i4i award to finance a Phase II Clinical (SCRATCH-HTN) confirmatory trial and to develop and CE mark its novel non-invasive device based solution. SCRATCH-HTN is a Sham controlled Randomized Control Trial evaluating the Safety, Acceptability and Efficacy of Autonomic neuromodulation using trans-cutaneous auricular sensory stimulation in uncontrolled hypertensive patients.
https://www.qmul.ac.uk/whri/research/scratch-htn/
Afferent receives a £1.1 million i4i award to finance a Phase II(SCRATCH-HTN) confirmatory trial and to develop and CE mark its novel non-invasive device based solution. SCRATCH-HTN is a Sham controlled Randomized Control Trial evaluating the Safety, Acceptability and Efficacy of Autonomic neuromodulation using trans-cutaneous auricular sensory stimulation in uncontrolled hypertensive patients.
Link to Study: